Pharma Mar, S.A. Latest Q3 Results and Analyst Forecasts
Pharma Mar, S.A. (BME:PHM) released its third-quarter results last week, providing a clear view of its current performance. The company reported revenues of €36 million, exceeding analyst forecasts by 6.5%.
Analyst Reactions and Forecast Updates
Following the earnings release, analysts updated their forecasts. The consensus now sees Pharma Mar generating €265.5 million in revenues for 2026, representing a significant 48% growth compared to the previous 12 months.
Statutory earnings per share (EPS) are expected to rise by 143%, reaching €4.80.
Changes in Analyst Expectations
Before these results, analysts had forecasted higher figures, with revenues of €285.3 million and EPS of €5.28 for 2026. The recent report has led to a more cautious outlook, as reflected in the lowered revenue and EPS predictions.
"Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.
Summary
The latest Pharma Mar earnings surpassed short-term expectations but prompted analysts to slightly reduce their longer-term revenue and earnings growth forecasts.